trial

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

NCTId NCT00167310
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 57 (actual)
Sponsored by University of Pittsburgh Medical Center
Primary completion 2015-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
57 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2005-09
Primary completion
2015-12
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Eicosapentaenoic acid (omega-3 fatty acid)

Sponsors

University of Pittsburgh Medical CenterLead Sponsor
American Heart AssociationCollaborator
VA Pittsburgh Healthcare SystemCollaborator

Investigators

1
Jeffrey K Yao, Ph.D., FACBPrincipal Investigator

Sites

1 total
Pittsburgh, United States

Linked catalysts

1
Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Aci — primary completion2015-12

Facts & assertions

4 sourced
Enrollment
57
Phase
PHASE2
Primary Completion Date
2015-12
Status
COMPLETED
relationships
The graph out of here
drug
Eicosapentaenoic acid (omega-3 fatty acid)
drug
lead_sponsor
University of Pittsburgh Medical Center
company
collaborator
American Heart Association
company
VA Pittsburgh Healthcare System
company
indication
Bipolar Disorder
indication
Schizoaffective Disorder
indication
Coronary Artery Disease
indication
investigator
Jeffrey K Yao, Ph.D., FACB
person